Abstract
We report on a 28-year-old man with hematemesis, renal dysfunction, and arterial hypertension who suffered from an acute gouty attack presenting as podagra. Because of the accompanying symptoms conventional treatment of the gouty attack with colchicine or nonsteroidal anti-inflammatory drugs was contraindicated. We treated the pain of acute arthritis with the specific 5-hydroxytryptamine subtype 3 receptor antagonist ondansetron. Within 30 min after intravenous injection of this drug a substantial degree of pain relief had occurred. Unwanted side effects due to treatment were not observed. It is suggested that the 5-hydroxytryptamine released during a gouty attack induces pain via activation of 5-hydroxytryptamine subtype 3 receptors on nociceptive afferent nerve fibers. 5-Hydroxytryptamine subtype 3 receptor antagonists may therefore be a novel class of drugs for the effective treatment of acute gouty attacks when conventional treatment is contraindicated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- 5-HT:
-
5-hydroxytryptamine
References
Eschalier A, Kayser V, Guilbaud G (1989) Influence of a specific 5-HT3 antagonist on carrageenan-induced hyperalgesia in rats. Pain 36:249–255
Fitzgerald M (1989) Arthritis and the nervous system. Trends Neurosci 12:86–87
Fozard JR (1989) The development and early clinical investigation of selective 5-HT3 receptor antagonists. In: Fozard JR (ed) The peripheral actions of 5-hydroxytryptamine. Oxford University Press, Oxford, pp 354–376
Gilliland BC, Gardner GC (1993) Rheumatic disorders. In: Ramsey PG, Larson EB (eds) Medical therapeutics. Saunders, Philadelphia, pp 488–521
Giordano J, Dyche J (1989) Differential analgesic actions of serotonin 5-HT3 receptor antagonists in the mouse. Neuropharmacology 28:423–427
Giordano J, Rogers LV (1989) Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats. European J Pharmacol 170:83–86
Lembeck F (1983) Mediators of vasodilatation in the skin. Br J Dermatol 109 [Suppl 25]:1–9
Levine JD, Moskowitz MA, Basbaum Al (1985) The contribution of neurogenic inflammation in experimental arthritis. J Immunol 135:843s-847s
Markham A, Sorkin EM (1993) Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 45:931–952
Marshall M, Schattenkirchner M (1976) Verlauf der Gicht. In: Zöllner N, Gröbner W (eds) Gicht. Handbuch der inneren Medizin, vol 7. Springer, Berlin Heidelberg New York, pp 255–264
Richardson BP (1990) Serotonin and nociception. Ann NY Acad Sci 600:511–520
Richardson BP, Engel G, Donatsch P, Stadler PA (1985) Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 316:126–131
Star V, Hochberg MC (1993) Prevention and management of gout. Drugs 45:212–222
Woolf AD, Dieppe PA (1987) Mediators of crystal-induced inflammation in the joint. Br Med Bull 43:429–444
Wyngaarden JB (1992) Gout. In: Wyngaarden JB, Smith LH Jr, Bennett JC (eds) Cecil textbook of medicine. Saunders, Philadelphia, pp 1107–1115
Author information
Authors and Affiliations
Additional information
Correspondence to: H. Schworer
Rights and permissions
About this article
Cite this article
Schwörer, H., Ramadori, G. Treatment of acute gouty arthritis with the 5-hydroxytryptamine antagonist ondansetron. Clin Investig 72, 811–813 (1994). https://doi.org/10.1007/BF00180553
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00180553